Tanzina Khan, MD
Anesthesiology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 27
- 7 carriers
- Office
- 1
Offices
1 location · Justin Lo MD A Professional Medical Corporation · 3 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
27 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khan’s office at (408) 295-8628 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
27 of 27 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A134243 · Current
Licensed to practise in California · since 2015 · expires 2028-07-31 · State University of New York Health Science Center at Brooklyn.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$120,672
Medicare paid this office $120,672 for 315 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 246 | $65,269 | $81 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 76 | $11,658 | $124 |
| New patient visit (45+ min) | 70 | $9,834 | $140 |
| New patient visit (30+ min) | 71 | $7,288 | $103 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 14 | $3,167 | $226 |
See all 17 services
| Short return visit (20+ min) | 246 | $65,269 | $81 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 76 | $11,658 | $124 |
| New patient visit (45+ min) | 70 | $9,834 | $140 |
| New patient visit (30+ min) | 71 | $7,288 | $103 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 14 | $3,167 | $226 |
| Return visit (30+ min) | 28 | $3,157 | $105 |
| Short return visit | 43 | $2,660 | $53 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 12 | $2,338 | $123 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 38 | $2,037 | $46 |
| Injection of trigger points, 1-2 muscles | 33 | $1,889 | $51 |
| Injection of substance into middle or upper spine canal using imaging guidance | 16 | $1,662 | $98 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 12 | $1,259 | $66 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 13 | $960 | $74 |
| Injection of drug or substance under skin or into muscle | 47 | $787 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 41 | $63 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 22 | $0 | None |
| Injection, bupivicaine, not otherwise specified, 0.5 mg | 13 | $0 | None |
Who their Medicare patients are
315 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 15% · Women 74% · Also on Medicaid 34% · Health risk score 1.24. At or below the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 75% · Diabetes 34% · Coronary heart disease 28% · Depression 27% · Chronic kidney disease 24% · Atrial fibrillation 16% · Cancer 13% · Heart failure 12% · Stroke 10% · COPD 9% · Dementia 9%.
The office billed $1,179,319, Medicare allowed $161,888 and paid $120,672; for 1,719 services of 37 kinds; $1,056 of it was for drugs given in the office and $119,616 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 315 | 1,719 | 76 | 1.24 | $1,179,319 | $120,672 |
| 2023 | 294 | 2,076 | 76 | 1.21 | $1,192,116 | $126,007 |
| 2022 | 223 | 1,634 | 75 | 1.27 | $1,160,065 | $116,701 |
| 2021 | 153 | 979 | 75 | 1.46 | $815,984 | $82,205 |
| 2020 | 149 | 650 | 73 | 1.50 | $336,146 | $38,367 |
| 2019 | 191 | 1,587 | 70 | 1.26 | $650,435 | $84,719 |
| 2018 | 144 | 841 | 70 | 1.21 | $413,595 | $51,030 |
| 2017 | 104 | 318 | 69 | 1.50 | $292,061 | $28,931 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Short return visit (20+ min) | 222 | $57,109 | $79 |
| Return visit (30+ min) | 108 | $19,307 | $114 |
| New patient visit (45+ min) | 99 | $14,147 | $143 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 67 | $9,801 | $123 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 14 | $3,619 | $259 |
| New patient visit (30+ min) | 31 | $3,102 | $100 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 41 | $1,978 | $46 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 16 | $1,886 | $111 |
| Injection of trigger points, 1-2 muscles | 29 | $1,699 | $50 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 12 | $814 | $63 |
| Injection of drug or substance under skin or into muscle | 41 | $674 | $13 |
| Short return visit | 13 | $500 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 29 | $42 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 35 | $1 | None |
2022: 16 services
| Short return visit (20+ min) | 173 | $58,727 | $82 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 72 | $12,063 | $127 |
| New patient visit (30+ min) | 96 | $9,296 | $97 |
| Return visit (30+ min) | 42 | $7,468 | $120 |
| New patient visit (45+ min) | 40 | $6,062 | $152 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 11 | $2,841 | $237 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 17 | $2,762 | $115 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 35 | $2,046 | $48 |
| Injection of substance into middle or upper spine canal using imaging guidance | 16 | $1,911 | $96 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 17 | $1,524 | $63 |
| Short return visit | 15 | $883 | $55 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 54 | $813 | $11 |
| Injection of trigger points, 1-2 muscles | 12 | $633 | $49 |
| Injection of drug or substance under skin or into muscle | 17 | $271 | $14 |
| Testing for presence of drug, read by direct observation | 11 | $137 | $12 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 15 | $0 | None |
2021: 11 services
| Short return visit (20+ min) | 109 | $27,357 | $83 |
| Return visit (30+ min) | 74 | $22,258 | $124 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 32 | $5,934 | $129 |
| New patient visit (30+ min) | 55 | $5,483 | $100 |
| New patient visit (45+ min) | 20 | $2,789 | $139 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 14 | $2,535 | $127 |
| Radiological supervision and interpretation x-ray of covering of spinal cord | 39 | $1,968 | $36 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 14 | $1,408 | $70 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 18 | $1,179 | $49 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 42 | $910 | $11 |
| Short return visit | 17 | $617 | $32 |
2020: 8 services
| Short return visit (20+ min) | 91 | $12,718 | $68 |
| Anesthesia for x-ray procedure (accessed through the skin) on spine and spinal cord | 31 | $5,583 | $114 |
| New patient visit (30+ min) | 38 | $4,011 | $106 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 11 | $3,872 | $242 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 14 | $1,832 | $131 |
| Radiological supervision and interpretation x-ray of covering of spinal cord | 17 | $632 | $37 |
| Testing for presence of drug, read by instrument assisted observation | 13 | $406 | $17 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $228 | $11 |
2019: 8 services
| Anesthesia for x-ray procedure (accessed through the skin) on spine and spinal cord | 115 | $26,163 | $109 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 25 | $13,067 | $242 |
| Short return visit (20+ min) | 72 | $11,945 | $63 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 13 | $4,384 | $219 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 13 | $1,917 | $96 |
| New patient visit (30+ min) | 20 | $1,790 | $90 |
| Testing for presence of drug, read by instrument assisted observation | 27 | $999 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $72 | None |
2018: 6 services
| Anesthesia for x-ray procedure (accessed through the skin) on spine and spinal cord | 87 | $19,331 | $109 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 22 | $9,921 | $242 |
| Short return visit (20+ min) | 47 | $6,291 | $62 |
| New patient visit (30+ min) | 19 | $1,922 | $101 |
| Testing for presence of drug, read by instrument assisted observation | 18 | $651 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $31 | None |
2017: 2 services
| Anesthesia for x-ray procedure (accessed through the skin) on spine and spinal cord | 81 | $19,340 | $117 |
| Short return visit (20+ min) | 13 | $1,505 | $65 |
Medicaid work
$1,133 in 2024
Medicaid paid $1,133 for 563 billed services this clinician did in 2024, up to 68 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 563 | $1,133 |
| 2024 | 563 | 1 | 68 | $1,133 |
| 2023 | 769 | 2 | 77 | $1,882 |
| 2022 | 640 | 3 | 62 | $524 |
| 2020 | 105 | 1 | 23 | $5,210 |
| 2019 | 229 | 1 | 26 | $10,950 |
| 2018 | 47 | 1 | 19 | $2,177 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 757 | $1,881 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 12 | $2 |
2022
| Short return visit (20+ min) | 571 | $472 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 54 | $52 |
| New patient visit (30+ min) | 15 | $0 |
2020
| Short return visit (20+ min) | 105 | $5,210 |
2019
| Short return visit (20+ min) | 229 | $10,950 |
2018
| Short return visit (20+ min) | 47 | $2,177 |
Drugs they prescribed that Part D paid
$54,604
Pharmacies billed $54,604 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 15% of their Part D prescriptions (277 of 1,817) in 2024. Above the middle of the specialty; the typical anesthesiology clinician is at 0%.
1,781 generic and 36 brand-name prescriptions · $54,604 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pregabalin | 182 | $8,358 | $46 |
| Gabapentin | 509 | $6,267 | $12 |
| Lidocaine | 32 | $5,153 | $161 |
| Duloxetine | 211 | $2,962 | $14 |
| Hydrocodone-Acetaminophen | 112 | $2,084 | $19 |
See all 20 drugs
| Pregabalin | 182 | $8,358 | $46 |
| Gabapentin | 509 | $6,267 | $12 |
| Lidocaine | 32 | $5,153 | $161 |
| Duloxetine | 211 | $2,962 | $14 |
| Hydrocodone-Acetaminophen | 112 | $2,084 | $19 |
| Tizanidine | 193 | $1,681 | $9 |
| Oxycodone-Acetaminophen | 54 | $992 | $18 |
| Diclofenac | 59 | $620 | $11 |
| Cyclobenzaprine | 57 | $584 | $10 |
| Baclofen | 36 | $560 | $16 |
| Nortriptyline | 31 | $490 | $16 |
| Celecoxib | 23 | $444 | $19 |
| Tramadol | 56 | $345 | $6 |
| Acetaminophen-Codeine | 16 | $264 | $16 |
| Amitriptyline | 11 | $217 | $20 |
| Naproxen | 57 | $208 | $4 |
| Diclofenac | 13 | $158 | $12 |
| Hydromorphone | 25 | $147 | $6 |
| Meloxicam | 36 | $101 | $3 |
| Diazepam | 23 | $36 | $2 |
Year by year
| 2024 | 1,817 | 384 | 15% (277) | 2% | $54,604 |
| 2023 | 1,934 | 368 | 18% (356) | 2% | $70,616 |
| 2022 | 1,793 | 295 | 21% (371) | 2% | $47,745 |
| 2021 | 1,400 | 198 | 28% (389) | 1% | $28,714 |
| 2020 | 547 | 127 | 41% (222) | 7% | $22,585 |
| 2019 | 633 | 70 | 48% (306) | 13% | $59,703 |
| 2018 | 364 | 59 | 42% (151) | 21% | $45,890 |
| 2017 | 196 | 71 | 18% (35) | 10% | $15,291 |
| 2016 | 332 | 110 | 11% (38) | None | $52,944 |
| 2015 | 18 | 11 | None | None | $3,617 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Pregabalin | 297 | $21,444 | $72 |
| Gabapentin | 483 | $7,562 | $16 |
| Lidocaine | 21 | $5,607 | $267 |
| Diclofenac | 137 | $3,426 | $25 |
| Hydrocodone-Acetaminophen | 125 | $2,600 | $21 |
| Duloxetine | 94 | $2,484 | $26 |
| Tizanidine | 180 | $2,362 | $13 |
| Oxycodone-Acetaminophen | 62 | $1,295 | $21 |
| Baclofen | 63 | $1,118 | $18 |
| Nortriptyline | 37 | $502 | $14 |
| Tramadol | 82 | $498 | $6 |
| Cyclobenzaprine | 48 | $403 | $8 |
| Hydromorphone | 38 | $376 | $10 |
| Meloxicam | 41 | $361 | $9 |
| Rizatriptan | 14 | $303 | $22 |
| Naproxen | 43 | $281 | $7 |
| Acetaminophen-Codeine | 22 | $267 | $12 |
| Methocarbamol | 14 | $147 | $11 |
| Diazepam | 23 | $15 | $1 |
2022: 19 drugs
| Pregabalin | None | 252 | $9,413 | $37 |
| Emgality | Migraine | 12 | $7,597 | $633 |
| Gabapentin | None | 519 | $7,103 | $14 |
| Duloxetine | None | 116 | $3,353 | $29 |
| Hydrocodone-Acetaminophen | None | 154 | $2,927 | $19 |
| Diclofenac | None | 92 | $2,411 | $26 |
| Tizanidine | None | 110 | $1,433 | $13 |
| Baclofen | None | 47 | $971 | $21 |
| Oxycodone-Acetaminophen | None | 48 | $849 | $18 |
| Nortriptyline | None | 51 | $589 | $12 |
| Cyclobenzaprine | None | 32 | $493 | $15 |
| Tramadol | None | 80 | $429 | $5 |
| Naproxen | None | 47 | $278 | $6 |
| Amitriptyline | None | 13 | $253 | $19 |
| Topiramate | None | 16 | $230 | $14 |
| Meloxicam | None | 36 | $229 | $6 |
| Acetaminophen-Codeine | None | 24 | $228 | $10 |
| Hydromorphone | None | 33 | $199 | $6 |
| Oxycodone | None | 13 | $167 | $13 |
2021: 18 drugs
| Pregabalin | 194 | $7,540 | $39 |
| Gabapentin | 395 | $6,225 | $16 |
| Lidocaine | 11 | $2,268 | $206 |
| Hydrocodone-Acetaminophen | 129 | $2,026 | $16 |
| Diclofenac | 33 | $1,531 | $46 |
| Duloxetine | 77 | $1,303 | $17 |
| Tizanidine | 95 | $1,040 | $11 |
| Oxycodone-Acetaminophen | 36 | $599 | $17 |
| Oxycodone | 32 | $581 | $18 |
| Tramadol | 91 | $428 | $5 |
| Cyclobenzaprine | 36 | $426 | $12 |
| Hydromorphone | 50 | $415 | $8 |
| Nortriptyline | 40 | $370 | $9 |
| Baclofen | 24 | $322 | $13 |
| Amitriptyline | 17 | $232 | $14 |
| Naproxen | 20 | $198 | $10 |
| Acetaminophen-Codeine | 34 | $151 | $4 |
| Meloxicam | 26 | $61 | $2 |
2020: 13 drugs
| Oxycontin | 11 | $3,305 | $300 |
| Gabapentin | 137 | $1,990 | $15 |
| Oxycodone-Acetaminophen | 47 | $1,729 | $37 |
| Pregabalin | 24 | $1,247 | $52 |
| Hydrocodone-Acetaminophen | 42 | $798 | $19 |
| Oxycodone | 40 | $673 | $17 |
| Tizanidine | 40 | $575 | $14 |
| Hydromorphone | 19 | $268 | $14 |
| Tramadol | 28 | $252 | $9 |
| Duloxetine | 13 | $204 | $16 |
| Nortriptyline | 14 | $97 | $7 |
| Methadone | 12 | $75 | $6 |
| Topiramate | 18 | $69 | $4 |
2019: 14 drugs
| Xtampza Er | 12 | $17,630 | $1,469 |
| Oxycontin | 23 | $12,096 | $526 |
| Nucynta Er | 11 | $8,716 | $792 |
| Oxycodone-Acetaminophen | 90 | $5,275 | $59 |
| Gabapentin | 147 | $2,356 | $16 |
| Lidocaine | 14 | $2,012 | $144 |
| Oxycodone | 78 | $1,484 | $19 |
| Hydrocodone-Acetaminophen | 34 | $928 | $27 |
| Tizanidine | 39 | $767 | $20 |
| Diclofenac | 22 | $548 | $25 |
| Tramadol | 11 | $519 | $47 |
| Methadone | 24 | $266 | $11 |
| Duloxetine | 14 | $171 | $12 |
| Diazepam | 11 | $27 | $2 |
2018: 10 drugs
| Lyrica | 13 | $7,850 | $604 |
| Nucynta Er | 11 | $7,599 | $691 |
| Lidocaine | 26 | $5,014 | $193 |
| Oxycodone-Acetaminophen | 44 | $2,468 | $56 |
| Gabapentin | 77 | $1,323 | $17 |
| Hydrocodone-Acetaminophen | 29 | $952 | $33 |
| Oxycodone | 19 | $698 | $37 |
| Tramadol | 18 | $667 | $37 |
| Duloxetine | 17 | $510 | $30 |
| Tizanidine | 21 | $428 | $20 |
2017: 4 drugs
| Lidocaine | 43 | $6,942 | $161 |
| Gabapentin | 61 | $595 | $10 |
| Tizanidine | 18 | $278 | $15 |
| Hydrocodone-Acetaminophen | 13 | $158 | $12 |
2016: 4 drugs
| Lidocaine | 88 | $18,573 | $211 |
| Gabapentin | 107 | $656 | $6 |
| Tizanidine | 42 | $516 | $12 |
| Meloxicam | 21 | $30 | $1 |
Money from drug and device companies
$229 in 2025
| 2025 | 5 | 8 | None | $229 |
| 2024 | 9 | 11 | None | $370 |
| 2023 | 14 | 23 | None | $720 |
| 2022 | 17 | 41 | None | $1,791 |
| 2021 | 8 | 21 | None | $840 |
| 2020 | 1 | 3 | None | $75 |
| 2019 | 2 | 10 | None | $987 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Intracept | $138 | 4 payments
|
| Medtronic | Kyphon Express II Kyphopak Tray | $26 | 1 payment
|
| Globus Medical | Senza | $23 | 1 payment
|
| Abbvie | Ubrelvy | $21 | 1 payment
|
| Si-Bone | None | $21 | 1 payment
|
See all 8 published payments
| Globus Medical | Meals · 2025-12-15 | Senza | $23 |
| Boston Scientific | Meals · 2025-12-04 | Wavewriter Alpha Prime 16 | $4 |
| Abbvie | Meals · 2025-11-20 | Ubrelvy | $21 |
| Boston Scientific | Meals · 2025-11-07 | Wavewriter Alpha Prime 16 | $26 |
| Si-Bone | Meals · 2025-11-03 | None | $21 |
| Boston Scientific | Meals · 2025-10-22 | Intracept | $93 |
| Medtronic | Education · 2025-05-28 | Kyphon Express II Kyphopak Tray | $26 |
| Boston Scientific | Meals · 2025-05-08 | General - Pain Management | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $370
| Abbott Laboratories | Eterna | $78 | 1 payment
|
| Boston Scientific | None | $60 | 1 payment
|
| Saluda Medical Americas | Evoke | $53 | 2 payments
|
| Scilex Pharmaceuticals | Ztlido | $38 | 2 payments
|
| Biotronik Nro | Prospera | $37 | 1 payment
|
| Abbvie | Botox | $33 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $33 | 1 payment
|
| Nalu Medical | Nalu Neurostimulation System | $22 | 1 payment
|
| International Rehabilitative Sciences | Rs 4i Plus Sequential Stimulator | $17 | 1 payment
|
2023: $720
| Painteq | Painteq | $140 | 2 payments
|
| Boston Scientific | None | $97 | 4 payments
|
| Abbvie | Botox | $75 | 3 payments
|
| SPR Therapeutics | Sprint Pns System | $62 | 2 payments
|
| Merz Pharmaceuticals | Xeomin | $57 | 1 payment
|
| Abbott Laboratories | Proclaim | $48 | 2 payments
|
| Nalu Medical | Nalu Neurostimulation System | $41 | 2 payments
|
| Saluda Medical Americas | Evoke Scs | $38 | 1 payment
|
| Medtronic | Vanta Adaptivestim | $37 | 1 payment
|
| Averitas Pharma | Qutenza | $30 | 1 payment
|
| Si-Bone | None | $29 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido | $24 | 1 payment
|
| Fidia Pharma USA | Hymovis | $22 | 1 payment
|
| Pfizer | Nurtec Odt | $19 | 1 payment
|
2022: $1,791
| Boston Scientific | Wavewriter Alpha Prime 16 | $719 | 9 payments
|
| SPR Therapeutics | Sprint Pns System | $234 | 3 payments
|
| Mml US | Reactiv8 | $131 | 1 payment
|
| Abbvie | Botox | $109 | 4 payments
|
| Abbott Laboratories | Proclaim | $104 | 4 payments
|
| Fidia Pharma USA | Hymovis | $79 | 3 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $55 | 2 payments
|
| Nalu Medical | Nalu Neurostimulation System | $51 | 2 payments
|
| Scilex Pharmaceuticals | Ztlido | $49 | 3 payments
|
| Allergan | Botox | $49 | 2 payments
|
| Bioventus | Stimrouter Implantable Kit | $48 | 1 payment
|
| Hikma Pharmaceuticals USA | Kloxxado | $38 | 2 payments
|
| Medtronic | Accurian | $34 | 1 payment
|
| Relievant Medsystems | Intracept | $33 | 1 payment
|
| Si-Bone | None | $23 | 1 payment
|
| Almatica Pharma | Gralise | $21 | 1 payment
|
| Nevro | Omnia | $14 | 1 payment
|
2021: $840
| Abbott Laboratories | Proclaim Ipg | $512 | 14 payments
|
| Boston Scientific | General - Pain Management | $135 | 1 payment
|
| Painteq | Painteq | $76 | 1 payment
|
| GRT US Holding | Qutenza | $33 | 1 payment
|
| Nalu Medical | Nalu Neurostimulation System | $29 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $25 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $16 | 1 payment
|
| Xeris Pharmaceuticals | Keveyis | $13 | 1 payment
|
2020: $75
| Abbott Laboratories | Axium Ins Drg Ipg | $75 | 3 payments
|
2019: $987
| Medtronic USA | Intellis | $837 | 7 payments
|
| Abbott Laboratories | Neuromodulation Dspsbls and Accs | $151 | 3 payments
|
Professional record
- NPI
- 1194959775
- Licence
- CA A134243, NY 271526California A134243: Current · expires 2028-07-31
- Trained
- State University of New York Downstate Medical Center, 2009
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 208VP0014X (208VP0014X); Student in a training program (390200000X)
- Mailing address
- 2101 Forest Ave Ste 220a, San Jose, CA, 95128
- NPI first listed
- 2009-05-11
- NPI last updated
- 2020-12-29
- NPI record certified
- 2020-12-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4235 Main St, Flushing, NY, 11355